WeTrials
Active, not recruiting

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

What is this study?

This study is testing a new cancer-fighting medicine called sacituzumab tirumotecan compared to standard chemotherapy for people with a specific type of advanced lung cancer. Researchers want to see if this new treatment helps patients live longer and better than traditional chemotherapy after previous treatments have stopped working.

Who can participate?

You may be able to join if you have advanced nonsquamous non-small cell lung cancer with an EGFR mutation that has continued to grow after taking targeted treatments. Your previous treatment side effects must have mostly cleared up, and certain health conditions like Hepatitis or HIV must be well-managed.

What will happen?

Participants will be randomly placed into one of two groups to receive either the new study medicine or standard chemotherapy drugs. You will also receive supportive medications, such as steroids or antihistamines, to help keep you comfortable and prevent side effects.

Where and when?

The study has locations in Oakland, Roseville, and San Francisco, California. Currently, this study is active but not actively recruiting new participants.

Key Points
  • 1Tests a new medicine against standard chemotherapy for advanced lung cancer
  • 2Designed for patients whose cancer has progressed after EGFR inhibitor treatments
  • 3Currently active at multiple locations in California but not accepting new patients

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Non-small Cell Lung Cancer (NSCLC)

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.